Cargando…
Safety and efficacy of a docetaxel-5FU-oxaliplatin regimen with or without trastuzumab in neoadjuvant treatment of localized gastric or gastroesophageal junction cancer: A retrospective study
BACKGROUND: Triplet chemotherapy, with docetaxel-5FU-oxaliplatin FLOT regimen recently became the standard perioperative treatment for localized gastric cancer (GC). An adapted regimen called TeFOX was recently tested in metastatic setting and gave promising results. AIM: To determine safety and eff...
Autores principales: | Basso, Valeria, Orry, David, Fraisse, Jean, Vincent, Julie, Hennequin, Audrey, Bengrine, Leila, Ghiringhelli, Francois |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6700033/ https://www.ncbi.nlm.nih.gov/pubmed/31435464 http://dx.doi.org/10.4251/wjgo.v11.i8.634 |
Ejemplares similares
-
Irinotecan, docetaxel and oxaliplatin combination in metastatic gastric or gastroesophageal junction adenocarcinoma
por: Di Lauro, L, et al.
Publicado: (2007) -
Association of 5-FU Therapeutic Drug Monitoring to DPD Phenotype Assessment May Reduce 5-FU Under-Exposure
por: Dolat, Marine, et al.
Publicado: (2020) -
Docetaxel, oxaliplatin, 5FU, and trastuzumab as first-line therapy in patients with human epidermal receptor 2-positive advanced gastric or gastroesophageal junction cancer: Preliminary results of a phase II study
por: Roviello, Giandomenico, et al.
Publicado: (2018) -
Phase II study of epirubicin, oxaliplatin and docetaxel combination in metastatic gastric or gastroesophageal junction adenocarcinoma
por: Di Lauro, Luigi, et al.
Publicado: (2009) -
Irinotecan- vs oxaliplatin-based regimens for neoadjuvant chemotherapy in colorectal liver metastasis patients: A retrospective study
por: Liu, Wei, et al.
Publicado: (2022)